Febuxostat

USDailyMed:Febuxostat AU:B1 M04AA03(WHO) AU:S4(Prescription only)US:℞-onlyEU:Rx-only 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid 144060-53-7N 134018 6817 DB04854N 118173Y 101V0R1N2E D01206Y CHEBI:31596 ChEMBL1164729Y DTXSID8048650 Interactive image N#Cc1c(OCC(C)C)ccc(c1)c2nc(c(s2)C(=O)O)C InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)YKey:BQSJTQLCZDPROO-UHFFFAOYSA-NY Febuxostat, sold under the brand nameUloricamong others, is amedicationused long-term to treatgoutdue tohigh uric acid levels.It is generally recommended only for people who cannot takeallopurinol.It is takenby mouth. Common side effects include liver problems, nausea, joint pain, and a rash.Serious side effects include an increased risk of death as compared with allopurinol,Stevens–Johnson syndrome, andanaphylaxis.Use is not recommended duringpregnancyorbreastfeeding.It inhibitsxanthine oxidase, thus reducing production ofuric acidin the body. Febuxostat was approved for medical use in the European Union in 2008,and in the United States in 2009.Ageneric versionwas approved in 2019. The drug is sometimes referred to asFBX.